

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

ACUITAS THERAPEUTICS INC.,

Plaintiff,

v.

GENEVANT SCIENCES GMBH AND
ARBUTUS BIOPHARMA CORP.,

Defendants.

Case No. 1:22-CV-02229-ER

RULE 7.1 CORPORATE DISCLOSURE STATEMENT

Defendant Arbutus Biopharma Corp. (“Arbutus”) submits the following statement of its corporate interests pursuant to Rule 7.1 of the Federal Rules of Civil Procedure.

Arbutus hereby states that it has no parent corporation. Roivant Sciences Ltd., a publicly-held company, owns 10% or more of the stock of Arbutus Biopharma Corp.

Dated: April 15, 2022

By: /s/ Kira A. Davis

DURIE TANGRI LLP

Kira A. Davis

953 East 3rd Street

Los Angeles, CA 90013

Telephone: (213) 992-4499

Facsimile: (415) 236-6300

Email: kdavis@duriatangri.com

Attorney for Defendant

ARBUTUS BIOPHARMA CORP.

CERTIFICATE OF SERVICE

I hereby certify that on April 15, 2022 the within document was filed with the Clerk of the Court using CM/ECF which will send notification of such filing to the attorneys of record in this case.

/s/ Kira A. Davis

KIRA A. DAVIS